Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients

Sponsor
Tang-Du Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT02134093
Collaborator
(none)
120
3
17

Study Details

Study Description

Brief Summary

This study is to explore the effects of dexmedetomidine on postoperative cognitive dysfunction during one-lung ventilation in elder patients.

Condition or Disease Intervention/Treatment Phase
  • Drug: Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium
  • Drug: Dexmedetomidine
  • Drug: Normal saline
  • Drug: Maintenance of anesthesia , propofol, remifentanil,vecuronium
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Prevention
Official Title:
Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients -a Single-center, Randomized ,Double-blinded and Controlled Trial
Study Start Date :
Jul 1, 2014
Anticipated Primary Completion Date :
May 1, 2015
Anticipated Study Completion Date :
Dec 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Normal saline

Continuous pump infusion of normal saline with identical volume, compared with the low dose and high dose group,until the end of surgery

Drug: Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium
Anesthesia induction:midazolam (0.03~0.05 mg/kg), sufentanil(0. 5~0.8 μg/kg), etomidate ( 0.2~0.6mg/kg) and rocuronium(0.6mg/kg)

Drug: Normal saline
Continuous pump infusion normal saline with identical volume of dexmedetomidine.

Drug: Maintenance of anesthesia , propofol, remifentanil,vecuronium
Continuous infusion of propofol (3~6 mg/kg/h), remifentanil (0.05~0.3 μg/kg/min)is required to maintain Entropy within 40~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium (0.05~0.1mg/kg) as needed to maintain muscle relaxation.

Experimental: High dose group, dexmedetomidine

Continuous pump infusion dexmedetomidine at 1μg/kg for 15 minutes before anesthesia induction ,then continuous pump infusion dexmedetomidine at 0.4μg/kg/h until the end of surgery

Drug: Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium
Anesthesia induction:midazolam (0.03~0.05 mg/kg), sufentanil(0. 5~0.8 μg/kg), etomidate ( 0.2~0.6mg/kg) and rocuronium(0.6mg/kg)

Drug: Dexmedetomidine
Continuous pump infusion dexmedetomidine at 0.5μg/kg (low dose group)or 1μg/kg (high dose group)for 15 minutes before anesthesia induction,then followed by a continuous pump infusion at 0.2 μg/kg/h(low dose group)or 0.4μg/kg/h(high dose group) until the end of surgery.

Drug: Maintenance of anesthesia , propofol, remifentanil,vecuronium
Continuous infusion of propofol (3~6 mg/kg/h), remifentanil (0.05~0.3 μg/kg/min)is required to maintain Entropy within 40~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium (0.05~0.1mg/kg) as needed to maintain muscle relaxation.

Experimental: Low dose group, dexmedetomidine

Continuous pump infusion dexmedetomidine at 0.5μg/kg for 15 minutes before anesthesia induction ,then continuous pump infusion dexmedetomidine at 0.2μg/kg/h until the end of surgery

Drug: Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium
Anesthesia induction:midazolam (0.03~0.05 mg/kg), sufentanil(0. 5~0.8 μg/kg), etomidate ( 0.2~0.6mg/kg) and rocuronium(0.6mg/kg)

Drug: Dexmedetomidine
Continuous pump infusion dexmedetomidine at 0.5μg/kg (low dose group)or 1μg/kg (high dose group)for 15 minutes before anesthesia induction,then followed by a continuous pump infusion at 0.2 μg/kg/h(low dose group)or 0.4μg/kg/h(high dose group) until the end of surgery.

Drug: Maintenance of anesthesia , propofol, remifentanil,vecuronium
Continuous infusion of propofol (3~6 mg/kg/h), remifentanil (0.05~0.3 μg/kg/min)is required to maintain Entropy within 40~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium (0.05~0.1mg/kg) as needed to maintain muscle relaxation.

Outcome Measures

Primary Outcome Measures

  1. The change in memory [one day before operation, first day after operation]

    The change in memory will be evaluated by Controlled Oral Word Association Test ,Semantic Fluency test

  2. Cognitive function [one day before operation, first day after operation]

    Cognitive function will be evaluated by Mini-mentalStateExamination,Digit-Symbol Substitution Test ,Trail Making Test

  3. Postoperative anxiety [one day before operation, first day after operation]

    Self-evaluation of Depression Symptoms form,Self-Rating Anxiety Scale,Visual analog scales

Secondary Outcome Measures

  1. Heart rate [At the moment of entering operating room ,the moment of intubation,prior to one lung ventilation,10 minutes,30 minutes afer one lung ventilation,the end of operation and the moment of leaving the operating room]

  2. Bleeding volume [At the beginning of operation,at the end of operation,up to 24 hours]

  3. Total volume of fluid [At the beginning of operation,at the end of operation,up to 24 hours]

  4. Duration of one lung ventilation [At the beginning of one lung ventilation,at the end of one lung ventilation,an expected average of 3 hours]

  5. The total dose of anaesthetic drugs [At the beginning of surgery,at the end of surgery,up to 24 hours]

  6. The total dose of analgesic drugs [During perioperative period,up to 7 days]

  7. Blood pressure [At the moment of entering operating room ,the moment of intubation,prior to one lung ventilation,10 minutes,30 minutes afer one lung ventilation,the end of operation and the moment of leaving the operating room]

  8. Oxygen saturation [At the moment of entering operating room ,the moment of intubation,prior to one lung ventilation,10 minutes,30 minutes afer one lung ventilation,the end of operation and the moment of leaving the operating room]

  9. End-tidal carbon dioxide [At the moment of entering operating room ,the moment of intubation,prior to one lung ventilation,10 minutes,30 minutes afer one lung ventilation,the end of operation and the moment of leaving the operating room]

  10. Operation duration [At the beginning of surgery,at the end of surgery,up to 24 hours]

Eligibility Criteria

Criteria

Ages Eligible for Study:
55 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Written informed consent.

  • Ongoing one-lung ventilation surgery.

  • American Society of Anesthesiologists class I to III.

  • Aged between 55 and 75 years old.

  • Body Mass Index between 18 and 25 kg/m2.

Exclusion Criteria:
  • Systolic blood pressure more than 180 mmHg or lower than 90 mmHg,diastolic blood pressure more than 110 mmHg or lower than 60 mmHg.

  • Serious heart,liver,kidney, pulmonary, and endocrine disease or serious infection.

  • Suspected or confirmed difficult airway.

  • History of abnormal anesthesia.

  • Suspected of malignant hyperthermia.

  • Use of sedative and antidepressant drug or serious alcoholism

  • Mini-mental State Examination less than 17.

  • Highest academic degree below grade 6 in primary schools

  • Patients inability to exchange with serious visual and hearing impairment or mental disability.

  • History of shock.

  • Carotid artery stenosis and central nervous system disease such as stroke, epilepsy.

  • Allergic to investigational products or with other contraindication.

  • Participated in other study within 30 days .

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Tang-Du Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
YangLu, physician, Tang-Du Hospital
ClinicalTrials.gov Identifier:
NCT02134093
Other Study ID Numbers:
  • Tangdu sedation
First Posted:
May 8, 2014
Last Update Posted:
Jul 11, 2014
Last Verified:
Jul 1, 2014

Study Results

No Results Posted as of Jul 11, 2014